CRVS Corvus Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CRVS

Price (delayed)

$0.7049

Market cap

$32.82M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.87

Enterprise value

$11.1M

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company. Corvus' lead product candidate is CPI-006, a humanized monoclonal antibody directed against CD73 that has exhibited immunomodulatory activity and activation of immune cells ...

Highlights
The debt has contracted by 26% YoY and by 8% from the previous quarter
The quick ratio has contracted by 47% YoY and by 36% from the previous quarter
Corvus Pharmaceuticals's equity has decreased by 38% YoY and by 20% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.corvuspharma.com
Peers: OVID

Key stats

What are the main financial stats of CRVS
Market
Shares outstanding
46.55M
Market cap
$32.82M
Enterprise value
$11.1M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.51
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$40.73M
EBITDA
-$40.36M
Free cash flow
-$26.61M
Per share
EPS
-$0.87
Free cash flow per share
-$0.57
Book value per share
$1.39
Revenue per share
$0
TBVPS
$1.73
Balance sheet
Total assets
$80.35M
Total liabilities
$15.67M
Debt
$2.87M
Equity
$64.68M
Working capital
$37.29M
Liquidity
Debt to equity
0.04
Current ratio
3.67
Quick ratio
3.59
Net debt/EBITDA
0.54
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-42.5%
Return on equity
-49.1%
Return on invested capital
-79.2%
Return on capital employed
-61.4%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CRVS stock price

How has the Corvus Pharmaceuticals stock price performed over time
Intraday
2.91%
1 week
-2.1%
1 month
-10.76%
1 year
-58.54%
YTD
-17.07%
QTD
-17.07%

Financial performance

How have Corvus Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$33.71M
Net income
-$40.73M
Gross margin
N/A
Net margin
N/A
The operating income rose by 19% year-on-year but it has declined by 11% since the previous quarter
Corvus Pharmaceuticals's net income has decreased by 11% QoQ

Growth

What is Corvus Pharmaceuticals's growth rate over time

Valuation

What is Corvus Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.51
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has decreased by 10% QoQ
The price to book (P/B) is 64% lower than the 5-year quarterly average of 1.4 and 36% lower than the last 4 quarters average of 0.8
Corvus Pharmaceuticals's equity has decreased by 38% YoY and by 20% QoQ

Efficiency

How efficient is Corvus Pharmaceuticals business performance
The ROE is down by 25% since the previous quarter
The company's return on assets fell by 23% QoQ
Corvus Pharmaceuticals's return on invested capital has decreased by 9% QoQ

Dividends

What is CRVS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CRVS.

Financial health

How did Corvus Pharmaceuticals financials performed over time
CRVS's current ratio is down by 47% YoY and by 37% from the previous quarter
The quick ratio has contracted by 47% YoY and by 36% from the previous quarter
The debt is 96% less than the equity
Corvus Pharmaceuticals's equity has decreased by 38% YoY and by 20% QoQ
The debt has contracted by 26% YoY and by 8% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.